GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
GO:00605375 | Cervix | CC | muscle tissue development | 76/2311 | 403/18723 | 9.76e-05 | 1.27e-03 | 76 |
GO:00147064 | Cervix | CC | striated muscle tissue development | 72/2311 | 384/18723 | 1.76e-04 | 2.07e-03 | 72 |
GO:000206410 | Cervix | CC | epithelial cell development | 45/2311 | 220/18723 | 4.14e-04 | 4.21e-03 | 45 |
GO:00426924 | Cervix | CC | muscle cell differentiation | 69/2311 | 384/18723 | 8.12e-04 | 7.09e-03 | 69 |
GO:00519603 | Cervix | CC | regulation of nervous system development | 77/2311 | 443/18723 | 1.13e-03 | 9.30e-03 | 77 |
GO:00487365 | Cervix | CC | appendage development | 35/2311 | 172/18723 | 1.88e-03 | 1.39e-02 | 35 |
GO:00601735 | Cervix | CC | limb development | 35/2311 | 172/18723 | 1.88e-03 | 1.39e-02 | 35 |
GO:00511464 | Cervix | CC | striated muscle cell differentiation | 50/2311 | 283/18723 | 5.53e-03 | 3.19e-02 | 50 |
GO:00309003 | Cervix | CC | forebrain development | 64/2311 | 379/18723 | 5.53e-03 | 3.19e-02 | 64 |
GO:0150063 | Cervix | CC | visual system development | 63/2311 | 375/18723 | 6.58e-03 | 3.65e-02 | 63 |
GO:0001654 | Cervix | CC | eye development | 62/2311 | 371/18723 | 7.83e-03 | 4.13e-02 | 62 |
GO:0048880 | Cervix | CC | sensory system development | 63/2311 | 381/18723 | 9.29e-03 | 4.66e-02 | 63 |
GO:0061351 | Cervix | CC | neural precursor cell proliferation | 28/2311 | 145/18723 | 1.04e-02 | 4.97e-02 | 28 |
GO:00605376 | Endometrium | AEH | muscle tissue development | 83/2100 | 403/18723 | 2.57e-08 | 1.50e-06 | 83 |
GO:003052210 | Endometrium | AEH | intracellular receptor signaling pathway | 60/2100 | 265/18723 | 7.16e-08 | 3.77e-06 | 60 |
GO:00147065 | Endometrium | AEH | striated muscle tissue development | 75/2100 | 384/18723 | 1.06e-06 | 3.62e-05 | 75 |
GO:00016556 | Endometrium | AEH | urogenital system development | 67/2100 | 338/18723 | 2.30e-06 | 6.76e-05 | 67 |
GO:00720015 | Endometrium | AEH | renal system development | 61/2100 | 302/18723 | 3.43e-06 | 9.24e-05 | 61 |
GO:00018224 | Endometrium | AEH | kidney development | 57/2100 | 293/18723 | 2.25e-05 | 4.35e-04 | 57 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RARB | SNV | Missense_Mutation | | c.184N>C | p.Glu62Gln | p.E62Q | P10826 | protein_coding | deleterious(0.05) | possibly_damaging(0.864) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
RARB | SNV | Missense_Mutation | | c.205N>T | p.Pro69Ser | p.P69S | P10826 | protein_coding | deleterious(0.02) | possibly_damaging(0.839) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RARB | SNV | Missense_Mutation | | c.505N>C | p.Glu169Gln | p.E169Q | P10826 | protein_coding | tolerated(0.06) | benign(0.213) | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RARB | SNV | Missense_Mutation | | c.434G>A | p.Gly145Glu | p.G145E | P10826 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
RARB | SNV | Missense_Mutation | | c.206N>T | p.Pro69Leu | p.P69L | P10826 | protein_coding | deleterious(0.02) | possibly_damaging(0.887) | TCGA-C8-A132-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RARB | SNV | Missense_Mutation | | c.860N>A | p.Arg287Gln | p.R287Q | P10826 | protein_coding | deleterious(0.02) | possibly_damaging(0.812) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
RARB | SNV | Missense_Mutation | | c.1173N>C | p.Leu391Phe | p.L391F | P10826 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RARB | SNV | Missense_Mutation | | c.440N>T | p.Ser147Phe | p.S147F | P10826 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
RARB | SNV | Missense_Mutation | | c.1058N>C | p.Lys353Thr | p.K353T | P10826 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RARB | SNV | Missense_Mutation | | c.339G>C | p.Met113Ile | p.M113I | P10826 | protein_coding | deleterious(0) | possibly_damaging(0.794) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 53801005 | | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL464 | ETRETINATE | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135650917 | | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | PMID27336223-Compound-7 | | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 178102082 | ADAPALENE | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | Tamibarotene | TAMIBAROTENE | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | RETINOIC ACID | | 17001699 |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL1657 | TAZAROTENE | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | LGD-1550 | | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 178103534 | TAZAROTENE | |